

Exhibit 60


Quarterly Compliance Report to Board of Directors 4Q2014

Bert Weinstein
Vice President, Corporate Compliance
January 16, 2015

 **PURDUE**®

U.S. - 5

Bottom Line




Purdue continues to have strong systems and processes in place to prevent and detect violations of law, regulations and company policies, and to remediate issues before they become significant problems.

There have been no significant compliance issues in the 4th quarter, or in Full Year 2014

We have been focused on Hysingla ER launch preparations, and will be monitoring promotion activities


PURDUE[®]

U.S. - 6




1Q2014 Compliance Priorities

- During 1Q 2014 there were 35 categories of compliance risk identified with business heads, of which: 1 High, 12 Medium, and 22 Low.




U.S. - 7



2014 Year End Risk Reduction

- We worked with the business areas to reduce compliance risks to a controllable level for the High and Medium Compliance risk items, so that now there are 11 Medium and 24 Low risk items that are the focus of effort. This risk prioritization process is repeated annually.




U.S. - 8

Compliance Audits



- Completed 13 compliance audits in 2014
- Areas audited included: Aggregate Spend, Call Notes, Field Contact Reports, Medical Inquiries, HCP Contracts and Fair Market Value, Speaker Programs, Grants, Managed Care, Publications
- Out of these 13 audits, there were a total of 27 findings – 0 Critical, 18 Major, and 9 Minor. All findings have been satisfactorily resolved.





Sales Compliance Review Committee


- “SCRC” is a committee that addresses compliance-related issues arising within the Field Force.
- Compliance matters are surfaced in many ways, including, call note monitoring, Field Contact Reports, expense and other routine monitoring activities, reports via the Hotline; and from employees and others.
- There were 533 closed matters in 2014, involving 239 representatives; with 31 of these matters (6%) resulting in disciplinary action. Most resolutions involve various forms of coaching

Remediation	% Total
DM Coaching	76%
Coaching Letter	8%
No follow up	7%
Warning Letter	4%
RD Coaching	3%
Probation Letter	2%

Top 5 Issues Found	% Total
Product Indication	33%
Presentation / Products	22%
Adverse Events	14%
Unclear / Poorly Written	10%
Typo	8%



Most Important Investigation of 2014




- A Sales Representative contacted Compliance about a Regional Manager who might be directing an inappropriate promotion message comparing OxyContin to IR oxycodone based on “half-life.”
- Investigation determined there was significant messaging in call notes from only the East Central Region, with numerous interviews of East Central personnel, and lengthy investigation throughout 4th quarter
- Remediation included:
 - Meeting of entire Regional Management Team together with Sales Management, Corporate Compliance, Law, and Medical Services to address appropriate messaging
 - Bulletin to the field and written guidance provided to all sales managers regarding appropriate messaging
 - Disciplinary Action – Termination of RD, Warning Letter to one DM, coaching to multiple sales representatives
- Nevertheless, this matter is not significant such that we would reasonably expect government action

PURDUE

U.S. - 11

2014 Sunshine Act filing (2013 data)



- CMS published all industry data September 30th
- No news stories have focused on Purdue spend
- The “General Dollar” amount of \$3,774,933 is reported on the CMS website, and \$7,280,494 “Research Dollars” will be reported on a delayed basis to protect confidential R&D information (per Sunshine Act)

Applicable Manufacturer	General (# transactions)	Research (# Transactions)	Total Transactions	General Dollars	Research Dollars *	Total Dollars
Purdue Pharma L.P.	22,892	953	23,845	2,732,705.04	6,263,169.61	\$8,995,874.65
Rhodes Pharmaceuticals L.P.	1	13	14	87.56	646,708.70	\$646,796.26
Purdue Products L.P.	4	0	4	5,669.96	0	\$5,669.96
Purdue Neuroscience Company	0	77	77	0	361,266.46	\$361,266.46
Purdue Transdermal Technologies L.P.	2420	4	2424	1,036,125.59	9,349.54	\$1,045,475.13
Purdue Pharma of Puerto Rico	17	0	17	345.19	0	\$345.19
TOTAL	25,334	1,047	26,381	3,774,933.34	7,280,494.31	\$11,055,427.65

